Overview[5]
Cyclophosphate meglumine injection is a non-cardiac glycoside cardiotonic drug, mainly used for the treatment of heart failure, myocarditis, sick sinus syndrome, coronary heart disease, cardiomyopathy, and auxiliary treatment of arrhythmia. treat. In recent years, it has been widely used in clinical practice because of its precise curative effect, unique function and good safety performance.
Indications[1]
Cyclophosphate meglumine can be used for heart failure, myocarditis, sick sinus syndrome, coronary heart disease and cardiac myopathy, and can also be used for the auxiliary treatment of arrhythmia.
Pharmacology and Toxicology[1]
Cyclophosphate meglumine is a non-digitis cardiotonic agent that has positive inotropic effects, can increase myocardial contractility, improve myocardial blood pumping function, dilate blood vessels, reduce myocardial oxygen consumption, and improve myocardial cells. Metabolism, protects myocardium from ischemia and hypoxia; can improve sinoatrial node P cell function.
Pharmacokinetics[1]
When cyclophosphate meglumine enters the human body, its half-life in the blood is 60 to 150 minutes. Due to its good hydrophilicity and especially strong fat solubility, it can easily penetrate the fat-soluble cell membrane and enter the cardiomyocytes. To function, it is decomposed by phosphodiesterase to form 5-AMP, which is then degraded by 5-AMP enzyme into adenosine and phosphate. Cyclophosphate meglumine begins to take effect 10 to 20 minutes after administration. The peak effect is 1 to 2 hours, and the drug effect disappears in 6 to 8 hours.
Clinical application research[2-4]
Duan Haiyan et al. explored the effects of injection of cyclophosphate meglumine combined with ramipril on cardiac function and quality of life in patients with chronic heart failure (CHF). Methods: 79 CHF patients who were treated in Jiaozhou People’s Hospital from May 2016 to September 2018 were selected and divided into a control group (39 cases) and an observation group (40 cases) using the random number table method. The patients in the control group received ramipril to treat carbon black on the basis of conventional treatment, and the patients in the observation group received intravenous infusion of cyclophosphamide meglumine for injection on the basis of the control group. The left ventricular end-diastolic diameter (LVEDD), cardiac blood transfusion (CO), left ventricular ejection fraction (LVEF), Short Form Health Questionnaire (SF-36) score, and occurrence of adverse reactions were compared between the two groups before and after treatment.
Results: After treatment, the LVEF and CO of the observation group were higher than those of the control group, and LVEDD was lower than that of the control group, and the differences were statistically significant (all P<0.05). After treatment, the SF-36 scores of the two groups of patients were improved compared with before treatment. The SF-36 scores of the patients in the observation group were higher than those in the control group, and the differences were statistically significant (all P0.05).
Conclusion: Meglumine cyclophosphate combined with ramipril can effectively improve cardiac function and quality of life in patients with CHF.
Wang Shuli and others systematically evaluated the efficacy of cyclophosphate adenosine meglumine in the treatment of heart failure due to coronary atherosclerotic heart disease (referred to as coronary heart disease). Methods: A computer search was performed on the Chinese Journal Full-text Database, VIP Database, and Wanfang Database. The search time was from the establishment of each database to October 2018. Randomized controlled trials were included. The evaluation indicators included left ventricular ejection fraction, clinical efficacy, and heart rate per heart. Blood output. The Cochrane 5.1.0 Systematic Review Manual was used to evaluate the risk of bias, RevMan 5.3 software was used for Meta analysis, and the modified Jadad scale was used to evaluate the quality of the literature.
Results: A total of 11 randomized controlled trials were included, involving 878 patients; Meta-analysis results showed that the left ventricular ejection fraction of patients in the intervention group [MD=3. 39, 95% CI (2. 75, 4. 03), P <0. 000 01], clinical efficacy [OR=3. 32, 95% CI (1. 94, 5. 66), P < 0. 000 1], blood output per heart [MD = 0. 56 , 95%CI (0. 45, 0. 67), P < 0. 000 01] were significantly higher than the control group (P < 0. 05). Conclusion: Cyclophosphate meglumine is effective in treating coronary heart disease and heart failure.
Dairy et al. discussed the clinical efficacy of cyclophosphate meglumine in the treatment of elderly patients with chronic heart failure. Methods From January 2016 to January 2018, 92 elderly patients with chronic heart failure admitted to our hospital were selected as research data, and 46 cases in each group were randomly divided into two groups. The control group and the observation group were treated with conventional treatment, with the addition of cyclophosphate adenosine glucose. amine treatment, and the therapeutic effects and cardiac function improvement effects of the two groups were observed.
Results: The effective rate of treatment in the observation group��97.83%, and the control group was 86.96%, and the difference was statistically significant (P<0.05); before treatment, there was no statistically significant difference in the cardiac function indicators LVEF, LVEDV, and LVESV between the two groups; after treatment, the observation group's LVEF, LVEDV, LVESV, etc. were significantly improved, and were significantly better than those in the control group, and the difference was statistically significant (P<0.05); before treatment, there was no statistically significant difference in the expression of cytokines NT-proBNP and Hcy between the two groups; after treatment, the expression of NT-proBNP and Hcy in the observation group The improvement of proBNP and Hcy was significantly better than that of the control group, and the difference was statistically significant (P<0.05).
Conclusion: The use of conventional treatment and cyclophosphate meglumine treatment in the treatment of chronic heart failure in the elderly can further improve the therapeutic effect, significantly improve the patient’s cardiac function, and has high therapeutic value and is worthy of promotion.
Main reference materials
[1] Instructions for Cycladenosine Meglumine Injection
[2] Duan Haiyan, Liu Qihua. Effects of meglumine cyclophosphate combined with ramipril on cardiac function and quality of life in patients with chronic heart failure [J]. Chinese Electronic Journal of Heart and Rhythm, 2019(04): 217-219.
[3]Wang Shuli, Feng Wentao, Wang Qian. Systematic review of cyclophosphate meglumine in the treatment of coronary heart disease and heart failure [J]. China Pharmaceuticals, 2019, 28(17): 40-43.
[4]Dai Rui, Zhang Liangliang. The efficacy of cyclophosphate meglumine in the treatment of chronic heart failure in the elderly [J]. Contemporary Medicine, 2019, 25(22):160-161.
[5] [Chinese invention, Chinese invention authorization] CN03124559.5 cyclophosphate meglumine large infusion preparation and its preparation method and cyclophosphate meglumine content determination method [public]/cyclophosphate meglumine Large infusion preparation and preparation method thereof [Authorization]
